Onconova Therapeutics Announces Positive Preclinical Data for Third-Generation Oral CDK4/6 + ARK5 Inhibitor and dual FLT3 and Src inhibitor at 2017 American Association of Cancer Research...
Onconova Therapeutics, Inc. (ONTX)
Last onconova therapeutics, inc. earnings: 11/12 05:10 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.onconova.com/investor-overview
Company Research
Source: GlobeNewswire
Comparative biological studies with PalbociclibSingle-agent activity of ON 123300 in various models including multiple myeloma and lymphoma NEWTOWN, Pa., April 04, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (Nasdaq: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes, announced promising pre-clinical data for first-in-class dual inhibitor of CDK4/6 + ARK5, as well as a Type 1 novel inhibitor of FLT3 and Src pathways as a novel strategy for Acute Myeloid Leukemia (AML) therapy at the 2017 AACR Annual Meeting. The Company presented its findings in two poster presentations on April 3, 2017. ON 123300, an orally administered novel CDK4/6 + ARK5 inhibitor, exhibits potent antitumor activity in vivo: comparative studies with Palbociclib ON 123300, a third-generation potent CDK4/6 inhibitor that also inhibits ARK5 with low nanomolar potency, was
Show less
Read more
Impact Snapshot
Event Time:
ONTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ONTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ONTX alerts
High impacting Onconova Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ONTX
News
- Traws Pharma Announces New Employee Inducement Grants [Yahoo! Finance]Yahoo! Finance
- Onconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology Company [Yahoo! Finance]Yahoo! Finance
- Traws Pharma Announces New Employee Inducement GrantsGlobeNewswire
- Onconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology CompanyGlobeNewswire
- Onconova Therapeutics, Inc. (NASDAQ: ONTX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
ONTX
Earnings
- 11/14/23 - Beat
ONTX
Sec Filings
- 4/4/24 - Form 8-K
- 4/4/24 - Form DEFA14A
- 4/3/24 - Form 4
- ONTX's page on the SEC website